// App-Quantinova.ai

BSH19‐OR‐006 : Inhibition of C3 with APL‐2 Results in Normalisation of Markers of Intravascular and Extravascular Haemolysis in Patients with Paroxysmal Nocturnal Haemoglobinuria

Researchers

Presenter

  • R. Wong

Principal Investigators

  • H. Pullon

  • P. Deschatelets

  • C. Francois

  • M. Hamdani

  • S. Issargrisil

  • P. Johson

  • P. Niparuck

  • T. Numbenjapon

  • J. Sathar

  • L. Tan

  • E. Tse

  • F. Grossi

Medical Centers

  • Sir YK Pao Centre for Cancer & Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong

  • Waikato Hospital, Hamilton, New Zealand

  • Apellis Pharmaceuticals, Louisville

  • Apellis Pharmaceuticals, Boston, United States

  • Siriraj Hospital, Bangkok, Thailand

  • JPharma Solutions GmbH, Zurich, Switzerland

  • Ramathibodee Hospital

  • Phramongkutklao College of Medicine Bangkok Thailand

  • Ampang Hospital, Petlaing Jaya, Malaysia

  • Lisa Tan Pharma Consulting, Cambridge, United Kingdom

  • Queen Mary Hospital, Hong Kong, Hong Kong

Locations

  • Hong Kong

  • New Zealand

  • United States

  • Thailand

  • Switzerland

  • Malaysia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Genetic Disorder

  • Oncology (ONC)

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Gynaecological cancer

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • Complement 3

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved